Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 250,000 Shares of Company Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $70.36, for a total value of $17,590,000.00. Following the completion of the sale, the chief executive officer owned 50,000 shares in the company, valued at $3,518,000. The trade was a 83.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

NASDAQ TEM traded up $1.23 on Thursday, hitting $77.84. 4,770,696 shares of the stock were exchanged, compared to its average volume of 6,170,540. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $91.83. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The company has a market capitalization of $14.05 billion, a PE ratio of -54.06 and a beta of 3.54. The business’s fifty day moving average is $70.24 and its 200 day moving average is $56.99.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the prior year, the business earned ($0.22) EPS. Tempus AI’s quarterly revenue was up 21.6% on a year-over-year basis. Research analysts anticipate that Tempus AI, Inc. will post -1.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently bought and sold shares of TEM. Mirae Asset Global Investments Co. Ltd. bought a new stake in Tempus AI during the third quarter worth approximately $5,333,000. ProShare Advisors LLC increased its position in Tempus AI by 5.9% during the 3rd quarter. ProShare Advisors LLC now owns 6,500 shares of the company’s stock valued at $532,000 after purchasing an additional 360 shares during the period. Vise Technologies Inc. bought a new stake in Tempus AI during the 3rd quarter valued at $235,000. International Assets Investment Management LLC grew its position in shares of Tempus AI by 3,027.6% in the 3rd quarter. International Assets Investment Management LLC now owns 104,555 shares of the company’s stock worth $8,563,000 after buying an additional 101,212 shares during the last quarter. Finally, Partners Wealth Management LLC purchased a new position in Tempus AI during the 3rd quarter worth $241,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TEM has been the subject of a number of analyst reports. Stifel Nicolaus lowered their price objective on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. UBS Group initiated coverage on shares of Tempus AI in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 price objective for the company. Finally, Piper Sandler upgraded shares of Tempus AI from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $56.00 to $76.00 in a research report on Tuesday, September 1st. Eleven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $72.47.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.